Huayu Pharmaceutical announced that its wholly-owned subsidiary, Seacross Pharmaceuticals Ltd., recently received market authorization issued by the Uzbekistan Drug Administration for the company's products docetaxel injection, oxaliplatin injection, and irinotecan hydrochloride injection.
汇宇制药：多西他赛注射液等三项产品获得乌兹别克斯坦上市许可
Huayu Pharmaceutical: Three products, including docetaxel injection, have obtained market approval in Uzbekistan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.